30% oncology margin cap announced, sending shockwaves through India's specialty pharma sector.
Nandan Kulkarni, Director and India Healthcare Senior Research Analyst at Bernstein, warned that hospitals with in‑house oncology pharmacies will feel the brunt of the cap for at least the next few quarters. Hospitals will see reduced gross margins on cancer drugs, which could tighten their operating leverage.
For specialty players like Zydus Lifesciences and Lupin, the cap could be a double‑edged sword. While the 30% trim on trade margins tightens revenue per unit, the policy is expected to lift patient access, potentially boosting volumes of specialty oncology drugs. Kulkarni noted that higher volumes could offset margin erosion if the firms can scale.
Current data shows that Indian pharma firms spend roughly 7–8% of revenue on R&D and 4–5% on capital expenditure. These figures are below the benchmarks of global peers, suggesting limited flexibility to absorb the margin hit without restructuring. The cap may prompt firms to accelerate cost‑control and efficiency initiatives.
Looking ahead, Kulkarni predicts the impact on manufacturers will normalize within three to four quarters as inventory adjustments settle. Long‑term, the policy could spur demand for specialty medicines and drive growth if the sector can invest in research and AI capabilities. Investors are watching the unfolding, balancing short‑term margin pressure against potential volume upside.